Renaissance Technologies
STLN

Renaissance Technologies’s Starling Oncology STLN Stock Holding History

Renaissance Technologies’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.42M Buy
1,365,913
+463,104
+51% +$1.95M 0.01% 1221
2026
Q1 		$2.77M Buy
902,809
+180,909
+25% +$555K ﹤0.01% 1701
2025
Q4 		$2.57M Sell
721,900
-28,600
-4% -$106K ﹤0.01% 1709
2025
Q3 		$2.62M Buy
750,500
+293,000
+64% +$1M ﹤0.01% 1901
2025
Q2 		$938K Buy
457,500
+209,900
+85% +$525K ﹤0.01% 2554
2025
Q1 		$282K Buy
247,600
+65,600
+36% +$50.8K ﹤0.01% 2944
2024
Q4 		$56.2K Buy
182,000
+12,000
+7% +$3.11K ﹤0.01% 3369
2024
Q3 		$55.6K Sell
170,000
-169,400
-50% -$70.2K ﹤0.01% 3334
2024
Q2 		$156K Buy
339,400
+199,300
+142% +$170K ﹤0.01% 3095
2024
Q1 		$221K Buy
140,100
+50,800
+57% +$96.6K ﹤0.01% 3195
2023
Q4 		$182K Buy
89,300
+17,000
+24% +$29.5K ﹤0.01% 3161
2023
Q3 		$101K Sell
72,300
-3,342
-4% -$3.46K ﹤0.01% 3243
2023
Q2 		$42K Sell
75,642
-56,858
-43% -$30.1K ﹤0.01% 3646
2023
Q1 		$90K Buy
+132,500
New +$169K ﹤0.01% 3519

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Renaissance Technologies's STLN Position: Q2 2026 in Review

Renaissance Technologies increased its Starling Oncology (STLN) stake by 51% in Q2 2026, buying an estimated $1.95M and bringing the position to 1,365,913 shares worth $7.42M. The position accounts for 0.01% of the portfolio, ranked #1221.

Renaissance Technologies first reported a position in STLN in Q1 2023 and has held it in 14 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Renaissance Technologies held 1,365,913 shares of Starling Oncology worth $7.42M as of Q2 2026.
  • Renaissance Technologies bought 463,104 Starling Oncology shares in Q2 2026, an estimated $1.95M.
  • Starling Oncology made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1221 holding.
  • Renaissance Technologies first reported a position in Starling Oncology in Q1 2023 and has held it in 14 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.